The diagnosis and treatment of patients with brain tumors represents a particular challenge. Multiple disciplines of modern medicine are involved in both the diagnosis, e.g. neuropathology, neuroradiology, nuclear medicine, and the treatment, e.g. neurosurgery, radiation-oncology, neurology, medical oncology, of brain tumors. Neurooncology is thus a very interdisciplinary area of oncology and requires the excellent cooperation of multiple disciplines. Since early 2012 the activities at the University Hospital Zurich in the area of neurooncology are coordinated by the newly founded
Brain Tumor Center at the Cancer Center Zurich. The principles of diagnosis and management are summarized in German here:
Empfehlungen zur Diagnostik, Therapie und Nachsorge.
Diagnosis and treatment of brain tumors are a major focus of the Department of Neurology at the University Hospital in Zurich. We offer continuous counseling, treatment and follow-up of patients and their relatives from the Canton of Zurich as well as further Cantons of Switzerland as well as a counseling and treatment service for patients from foreign countries who visit Zurich only occasionally in larger intervals. The outpatient clinic is open Monday through Friday.
The interdisciplinary tumorboard takes place on Monday at 8.30. Brain tumor patients of the University Hospital Zurich as well from external institutions are discussed with their medical history. The corresponding pathology and imaging data are presented. We develop interdisciplinary recommendations for diagnosis and treatment which are accordingly documented. There is the opportunity for external colleagues to submit their patient cases with specific questions to our boards and present them either personally or through our team. Contacts for the interdisciplinary tumor boards are PD Dr. Patrick Roth (email@example.com), Dr. Dorothee Gramatzki (firstname.lastname@example.org, Dr. Katharina Seystahl (email@example.com), Dr. Tobias Weiss (firstname.lastname@example.org),
Dr. Hans-Georg-Wirsching (email@example.com) and Dr. Fabian Wolpert (firstname.lastname@example.org).
The enrolment of patients into clinical trials pursues the goal of further improving the standards of care for brain tumor patients. The initiation and coordination of clinical trials in Zurich is done in close cooperation of our department and the partner institutions at the Brain Tumor Center Zurich with clinical trial consortia such as the EORTC (European Organization for Research and Treatment of Cancer) as well as the pharmaceutical industry. Currently we offer participation in clinical trials for patients with newly diagnosed and recurrent
glioblastoma. Contacts for our ongoing clinical trials are indicated
Elderly patients with newly diagnosed glioblastoma or anaplastic astrocytoma or patients or adult relapsed patients with anaplastic astrocytoma or glioblastoma can participate in the phase Ib trial EORTC 1608-BTG evaluating the safety and tolerability of TGO2, an oral multi-kinase inhibitor.
The multicenter randomized phase III trial EORTC-1709-BTG investigates the efficacy of the proteasome inhibitor marizomib combined with radiotherapy and temozolomide in patients with newly diagnosed glioblastoma. Patients with recurrent glioblastoma can participate with the CDI-CS-003 phase I/IIa trial evaluating BAL101553, a microtubule targeting agent, for safety and tolerability. The BGB-290-104 trial is a multicenter phase I/IIa study to assess the safety, tolerability and efficacy of BGB-290, an inhibitor of the DNA repair enzyme poly (ADP-ribose)-polymerase (PARP), in combination with radiation therapy and/or temozolomide in patients with newly diagnosed or recurrent glioblastoma. The Gliomoon,
phase I/II trial evaluates the safety
and efficacy of the tumor-targeting human antibody-cytokine fusion protein
L19TNF in patients with IDH wildtype WHO grade III / IV glioma at first relapse.
Primary CNS lymphoma
Patients with recurrent primary CNS lymphoma can participate in the phase II trial PQR309-005, an open-label, non-randomized, study evaluating the efficacy and safety of the PQR309. Another trial for patients with recurrent primary CNS lymphoma represents the PCNSL01 trial (phase II) evaluating activity of pembrolizomab.
Donations for our scientific work (details here
) can be made via bank transfer to either of the following accounts:
Transfer to our postal giro account: Recipient: Rechnungswesen der Universität Zürich 8001 Zürich, giro account no.: 80-643-0, IBAN: CH46 0900 0000 8000 0643 0, BIC: POFICHBEXXX
Transfer to our bank account: Recipient: Universität Zürich CH-8001 Zürich, account no. 1100-0109.594(BC 700) - Zürcher Kantonalbank, CH-8010 Zürich, Swift-Code: ZKBKCHZZ80A, IBAN: CH51 0070 0110 0001 0959 4
For accounting purposes we would like to ask you to add the "payable to" notice as follows: "Zu Gunsten des Kontos F-86001-01-01". If you want to choose the intended purpose in detail, please contact us before or after your bank transfer (tel. +41 44 255 55 00). We will be pleased to send you an official confirmation of your donation by simply contacting us via our telephone number +41 44 255 55 00.
Prof. Dr. M. Weller
University Hospital Zurich
Department of Neurology